Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical, Morphological, and Electrophysiological Characteristics of MEK Inhibitor-Associated Retinopathy in Patients Treated With Combined BRAF/MEK Inhibitor Therapy for Malignant Melanoma

NCT07427953 is registered in ClinicalTrials.gov with Institute of Oncology Ljubljana as lead sponsor.

NCT NCT07427953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07427953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical, Morphological, and Electrophysiological Characteristics of MEK Inhibitor-Associated Retinopathy in Patients Treated With Combined BRAF/MEK Inhibitor Therapy for Malignant Melanoma
Lead sponsor
Institute of Oncology Ljubljana
Phase
Observational
Overall status
Completed
Start date
January 1, 2023
Completion date
January 31, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-induced retinopathy, malignant melanoma